BioMap unveils 11 AI and life science collaborations at Hong Kong Summit – Unite.AI

BioMap announced collaborations with 11 partners at the International Bio-Computing Innovation Summit 2026 in Hong Kong, extending its work on the underlying AI model to drug research, traditional Chinese medicine, agricultural breeding and overseas expansion. The summit opened at the Hong Kong Convention and Exhibition Center on November 6, 2026.

Seven projects were showcased at BioMap InnoHub’s morning launch ceremony, followed by collaborations involving four more organizations at an afternoon ceremony. BioMap hosted the event with the support of Hong Kong Investment Corporation Limited. The collaborations aim to advance AI research and applications in life sciences, while accelerating the commercialization of research results in Hong Kong.

Medical and agricultural projects

The University of Hong Kong collaboration advances the next phase of the Breast Cancer Virtual Cell Large Model project, using artificial intelligence to simulate the functioning of breast cancer cells and help researchers understand the disease. HKIC CEO Clara Chan said in her summit speech on November 6 that the phase II breast cancer model would be launched in 2026, after a previous multimodal breast cancer tumor cell foundation model was released at the 2025 summit.

Two other morning projects apply artificial intelligence to different forms of therapeutic research. BioMap and Hong Kong Baptist University plan to establish a joint traditional Chinese medicine laboratory on artificial intelligence, combining computational analysis with experimental validation to study how traditional Chinese medicine ingredients work. A separate new peptide drug incubation initiative with PepLib aims to accelerate research and development of peptide and cyclic peptide therapeutics.

Agriculture received a parallel boost. BioMap and Soy-Sky FarmTech will combine biologically based models with genetic data and crop characteristics in an AI-based breeding platform designed to support breeding decisions. The partners also plan an AI Belt and Road agricultural innovation ecosystem. Separately, BioMap will work with DEFTA partners on the DEFTA overseas market expansion program, exploring research and industry collaboration in Japan and other overseas markets.

Shared infrastructures and regional projects

Several collaborations focus on the infrastructure that connects models with experiments. BioMap’s initiative with Coyote Bioscience combines research translation in industry, academia and research institutions with an open cartridge ecosystem and supports collaboration on point-of-care molecular testing in Hong Kong. His work with HiDream.ai on a cross-scale virtual organism model will study biological phenomena at different scales and explore ways to predict and reconstruct their dynamics.

During the afternoon ceremony, BioMap said it will work with Temasek Life Sciences Laboratory on plans to jointly establish an AI bioinformatics center in Singapore. The center remains in the planning stage. Revvity is the partner of another planned facility: an AI biomanufacturing lab that integrates computational and experimental workflows in a closed loop.

MegaStream builds on a June partnership

The afternoon program also featured MegaStream TechBio, the drug development venture jointly founded by BioMap and Harbor BioMed. CEO Kyler Lei made his first public appearance, outlined a vision for drug discovery called AIDD 3.0, and discussed a pipeline organized around First-in-Class and Best-in-Class programs. That pitch built on a partnership already disclosed earlier in the year: Harbor BioMed’s June 15, 2026 announcement said the companies would launch MegaStream as a native AI pipeline company targeting global markets.

Under that plan, Harbor BioMed would contribute its fully human antibody platform, target biology expertise and global clinical development capabilities. BioMap would provide foundational artificial intelligence technology, model engineering, and intelligent research and development capabilities. MegaStream’s initial pipeline was to combine AI-identified candidates in previous partner collaborations with newly launched AI-driven discovery programs, prioritizing complex biologics in the cardiovascular, renal, oncology and anti-aging areas.

The June release also described a planned wet and dry discovery lab that linked computational design with experimental validation. Harbor BioMed expects efficiency gains of more than 500% over previous generation platforms, a more than tenfold increase in data accumulation efficiency, and more than 5 petabytes of AI-ready life sciences data within five years. These figures represent operational targets for the planned laboratory, rather than performance results announced at the November summit.

For BioMap, the proof of execution is whether this expanding network can transform model predictions and automated experiments into validated therapies, breeding tools, and commercial research results in the regions covered by the Summit partnerships.